2010擭乮暯惉22擭乯

榑暥

1.	Identification and characterization of early growth response 2, a zinc-finger transcription factor, as a p53-regulated proapoptotic gene.
	Yokota I, Sasaki Y, Kashima L, Idogawa M, Tokino T.
	Int J Oncol. 2010 Dec;37(6):1407-16.
	PMID: 21042708 [PubMed - indexed for MEDLINE]
	Related citations

2.	A novel correlation between LINE-1 hypomethylation and the malignancy of gastrointestinal stromal tumors.
	Igarashi S, Suzuki H, Niinuma T, Shimizu H, Nojima M, Iwaki H, Nobuoka T, Nishida T, Miyazaki Y, Takamaru H, Yamamoto E, Yamamoto H, Tokino T, Hasegawa T, Hirata K, Imai K, Toyota M, Shinomura Y.
	Clin Cancer Res. 2010 Nov 1;16(21):5114-23. Epub 2010 Oct 26.
	PMID: 20978145 [PubMed - indexed for MEDLINE]
	Related citations

3.	Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect.
	Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshikawa K, Kimura T, Kudo T, Harada E, Sugai T, Takamaru H, Niinuma T, Maruyama R, Yamamoto H, Tokino T, Imai K, Toyota M, Shinomura Y.
	Carcinogenesis. 2010 Dec;31(12):2066-73. Epub 2010 Oct 5.
	PMID: 20924086 [PubMed - indexed for MEDLINE]
	Related citations

4.	DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae.
	Yamashita M, Toyota M, Suzuki H, Nojima M, Yamamoto E, Kamimae S, Watanabe Y, Kai M, Akashi H, Maruyama R, Sasaki Y, Yamano H, Sugai T, Shinomura Y, Imai K, Tokino T, Itoh F.
	Cancer Sci. 2010 Jul;101(7):1708-16. Epub 2010 Apr 2.
	PMID: 20507321 [PubMed - indexed for MEDLINE]
	Related citations

5.	Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.
	Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, Ashida M, Ohe-Toyota M, Kai M, Nishidate T, Sasaki Y, Ohmura T, Hirata K, Tokino T.
	Breast Cancer Res Treat. 2010 Aug;122(3):699-710. Epub 2009 Oct 27.
	PMID: 19859801 [PubMed - indexed for MEDLINE]
	Related citations

6.	IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype.
	Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M, Akashi H, Watanabe Y, Yamamoto H, Sasaki Y, Itoh F, Imai K, Sugai T, Shen L, Issa JP, Shinomura Y, Tokino T, Toyota M.
	Carcinogenesis. 2010 Mar;31(3):342-9. Epub 2009 Jul 28.
	PMID: 19638426 [PubMed - indexed for MEDLINE] Free Article
	Related citations

妛夛敪昞

1. Tokino T, Kashima L, Toyota M, Sasaki Y. CHFR, a potential tumor suppressor, downregulates interleukin-8 via inhibition of NF-kB. American Association of Cancer Research (AACR) Annual Meeting. April 20th 2010, Washington DC, USA.
2. Idogawa M, Sasaki Y, Kashima L, Shinomura Y, Imai K, Tokino T.Single adenovirus-mediated simultaneous expression of p53 and the artificial microRNAs targeting anti-apoptotic p53 target genes.American Association of Cancer Research (AACR) annual meeting. 2010, Washington D.C.
3. Tokino T, Idogawa M, Sasaki Y. A single adenovirus expressing p53 protein and p21-targeting artificial microRNAs improves therapeutic outcome in cancer. 8th AACR-JCA Joint International Conference. 2010, Waikoloa, Hawaii.
4. Sasaki Y, Yokota I, Kashima L, Idogawa M, Suzuki H, Toyota M, Imai K, Shinomura Y, Tokino T. hCLCA2, a p53 inducible transmembrane protein regulates cancer cell migration and adhesion. 8th AACR-JCA Joint International Conference. 2010, Waikoloa, Hawaii.
5. Kashima L, Toyota M, Mita, Suzuki H, Idogawa M, Ogi K, Sasaki Y, Tokino T. CHFR, a potent tumor suppressor, downregulates interleukin-8 via inhibition of NF-kappaB. 8th AACR-JCA Joint International Conference. 2010, Waikoloa, Hawaii.
6. Yokota I, Sasaki Y, Anbo N, Kashima L, Idogawa M, Tokino T. Identification and characterization of early growth response gene-2 as a p53-regulated proapoptotic gene. 8th AACR-JCA Joint International Conference. 2010, Waikoloa, Hawaii.
7. Sasaki Y, Negishi H, Koyama R, Kusano M, Suzuki H, Fujita M, Toyota M, Tokino T. Negative regulation of hepatoma-derived growth factor by p53. 38th Congress of the International Society of Oncology and BioMarkers. 2010, Munchen, Germany.
8. 嵅乆栘懽巎丆崻娸廏柧丆墶揷堢巕丆幁搰棟嵐丆堜屗愳夒巎丆楅栘戱丆朙揷幚丆崱堜峗嶰丆幝懞嫳媣丆帪栰棽帄丏p53偵傛傝敪尰梷惂偝傟傞暘斿惈憹怋場巕HDGF偺摨掕丏戞69夞擔杮娻妛夛妛弍憤夛 2010, 戝嶃丏
9. 堜屗愳夒巎丆嵅乆栘懽巎丆幁搰棟嵐丆幝懞嫳媣丆崱堜峗嶰丆帪栰棽帄丏p53偲傾億僩乕僔僗慾奞揑昗揑偵懳偡傞miRNA偺扨堦傾僨僲僂僀儖僗敪尰偵傛傞娻帯椕丏戞69夞擔杮娻妛夛妛弍憤夛 2010, 戝嶃丏
10. 幁搰棟嵐丆尒揷桾復丆堜屗愳夒巎丆嵅乆栘懽巎丆帪栰棽帄丏偑傫梷惂暘巕CHFR偍傛傃PARP-1憡屳嶌梡偵傛傞嵶朎廃婜惂屼丏戞69夞擔杮娻妛夛妛弍憤夛 2010, 戝嶃丏
11. 墶揷堢巕丆嵅乆栘懽巎丆埨曐捈庽丆幁搰棟嵐丆堜屗愳夒巎丆帪栰棽帄丏p53僼傽儈儕乕偺昗揑堚揱巕EGR2偺摨掕偲婡擻夝愅丏戞69夞擔杮娻妛夛妛弍憤夛 2010, 戝嶃丏
12. 恄慜惓岾丆嶳杮塸堦榊丆楅栘戱丆嶳栰懽曚丆峛斻惓峀丆悰堜桳丆帪栰棽帄丆崱堜峗嶰丆幝懞嫳媣丆朙揷幚丏奼戝撪帇嬀偵傛傞CIMP梲惈戝挵娻偺慜偑傫昦曄偺恌抐丏戞69夞擔杮娻妛夛妛弍憤夛 2010, 戝嶃丏
13. 怴徖栆丆楅栘戱丆栰搰惓姲丆屲廫棐怢堦丆嶳杮塸堦榊丆崅娵攷擵丆揷徖摽恀丆嶳杮攷岾丆帪栰棽帄丆崱堜峗嶰丆朙揷幚丆幝懞嫳媣丏GIST偵偍偗傞LINE-1掅儊僠儖壔偲埆惈搙偺憡娭丏戞69夞擔杮娻妛夛妛弍憤夛 2010, 戝嶃丏
14. CIMP戝挵娻偺婲尮丏嶳杮塸堦榊丆楅栘戱丆嶳栰懽曚丆恄慜惓岾丆峛斻惓峀丆悰堜桳丆帪栰棽帄丆崱堜峗嶰丆幝懞嫳媣丆朙揷幚丏戞69夞擔杮娻妛夛妛弍憤夛 2010, 戝嶃丏
15. 郪揷晲丆嶳杮塸堦榊丆楅栘戱丆嶳栰懽曚丆恄慜惓岾丆峛斻惓峀丆悰堜桳丆帪栰棽帄丆崱堜峗嶰丆幝懞嫳媣丆埳搶暥惗丆朙揷幚丏愼怓懱晄埨掕惈偵娭楢偟偨戝挵態庮撪偺堎忢儊僠儖壔丏戞69夞擔杮娻妛夛妛弍憤夛 2010, 戝嶃丏
16. 栰搰惓姲丆朙揷幚丆楅栘戱丆帪栰棽帄丆幝懞嫳媣丆怷枮丏寣惔DNA傪棙梡偟偨DNA儊僠儖壔偲惗妶廗姷偺娭楢偵偮偄偰偺専摙丏戞69夞擔杮娻妛夛妛弍憤夛 2010, 戝嶃丏
17. 朙揷幚丆楅栘戱丆栰搰惓姲丆嵅乆栘懽巎丆幝懞嫳媣丆帪栰棽帄丆崱堜峗嶰丏師悽戙僔乕僋僄儞僒乕傪梡偄偨堚揱巕揮幨奐巒揰梊應偲僄僺僎僲儉夝愅傊偺墳梡丏戞69夞擔杮娻妛夛妛弍憤夛 2010, 戝嶃丏
18. 幁搰棟嵐, 尒揷桾復, 堜屗愳夒巎, 朙揷幚丆嵅乆栘懽巎,帪栰棽帄. The functional relationship between CHFR and PARP-1 controls the mitotic checkpoint and tumor development. 戞33夞擔杮暘巕惗暔妛夛擭夛丏2010, 恄屗
19. 悪嶁弤丆堜屗愳夒巎丆嵅乆栘懽巎丆幁搰棟嵐丆帪栰棽帄丏傾僨僲僂僀儖僗傪梡偄偨傾億僩乕僔僗慾奞揑p53昗揑堚揱巕偵懳偡傞恖岺miRNA偲p53偺摫擖偵傛傞娻嵶朎偱偺傾億僩乕僔僗桿摫丏戞33夞擔杮暘巕惗暔妛夛擭夛 2010丆恄屗丏
20. 暯栰梇戝丆嵅乆栘懽巎丆墶揷堢巕丆悪嶁弤丆幁搰棟嵐丆堜屗愳夒巎丆帪栰棽帄丏p53僼傽儈儕乕偺怴婯昗揑ICAM2偺摨掕丗偑傫嵶朎偺愙拝丒梀憱擻傊偺娭梌丏戞33夞擔杮暘巕惗暔妛夛擭夛 2010丆恄屗丏

尋媶彆惉

1. 帪栰棽帄丆壃榓峅丆暯捤攷媊丏嵶朎暘楐惂屼堚揱巕CHFR偺婡擻夝柧偍傛傃岥峯娻偺恌抐偲暘巕昗揑栻偺奐敪傊偺墳梡丏暯惉20-22擭搙暥晹壢妛徣壢妛尋媶旓曗彆嬥乮婎斦尋媶B乯丏
2. 帪栰棽帄丆屆敤抭媣丏RNA姳徛媄弍傪嬱巊偟偰傾億僩乕僔僗桿摫僔僌僫儖傪憹嫮偟偨堚揱巕帯椕朄偺奐敪丏暯惉21-22擭搙暥晹壢妛徣壢妛尋媶旓曗彆嬥乮朑夎尋媶乯丏
3. 嵅乆栘懽巎丏儕儃僝乕櫻抈敀幙偺敪尰堎忢傪昗揑偲偟偨徚壔婍娻偵懳偡傞恌抐丒帯椕朄偺奐敪丏暯惉20-22擭搙暥晹壢妛徣壢妛尋媶旓曗彆嬥乮婎斦尋媶C乯丏
4. 嵅乆栘懽巎丏p53偵惂屼偝傟傞non-coding RNA偺摨掕丗僶僀僆儅乕僇乕偲偟偰偺桳梡惈偲暘巕昗揑傊偺墳梡丏暯惉22擭搙乮2010擭乯戝嶃娻尋媶夛堦斒妛弍尋媶彆惉嬥丏
5. 嵅乆栘懽巎丏p53僼傽儈儕乕偺怴婯昗揑偺摨掕-偑傫偺怹弫丒揮堏偵娭傢傞暘巕偺夝愅丏暯惉22擭搙嶥杫堛壢戝妛妛弍怳嫽帠嬈彆惉乮尋媶幰摍奀奜攈尛乯
6. 堜屗愳夒巎丏p53/miRNA嫟敪尰儀僋僞乕偵傛傞傾億僩乕僔僗偲RNA姳徛傪梡偄偨暋崌娻帯椕丏暥晹壢妛徣 暯惉22-23擭搙 壢妛媄弍尋媶旓曗彆嬥乮庒庤尋媶B乯
7. 堜屗愳夒巎丏p53/miRNA嫟敪尰傾僨僲僂僀儖僗儀僋僞乕傪梡偄偨娻帯椕朄偺奐敪丏岞塿怣戸 彫栰偑傫尋媶彆惉婎嬥 暯惉21擭搙 尋媶彆惉嬥
8. 堜屗愳夒巎丏僎僲儉栐梾揑miRNA僗僋儕乕僯儞僌偵傛傞p53/miRNA嫟敪尰儀僋僞乕傪梡偄偨娻帯椕朄偺奐敪丏彫椦偑傫妛弍怳嫽夛 戞4夞偑傫栻暔椕朄偵娭偡傞愭嬱揑帯椕朄偵懳偡傞尋媶彆惉
9. 堜屗愳夒巎丏傾億僩乕僔僗桿摫抈敀偵RNA姳徛傪慻傒崌傢偣偨娻帯椕嵻偺奐敪丏僲乕僗僥僢僋嵿抍 暯惉22擭搙 尋媶奐敪彆惉帠嬈 庒庤尋媶恖嵽堢惉帠嬈 庒庤尋媶恖嵽丒僱僢僩儚乕僋堢惉曗彆嬥
10. 堜屗愳夒巎丏僎僲儉栐梾揑側恖岺miRNA偺僗僋儕乕僯儞僌偵傛傞p53/miRNA嫟敪尰儀僋僞乕傪梡偄偨娻帯椕朄偺奐敪丏晲揷壢妛怳嫽嵿抍 2010擭搙 尋媶彆惉乮堛妛宯尋媶彠椼乯丏
11. 堜屗愳夒巎丏恖岺miRNA傪梡偄偨僎僲儉栐梾揑僗僋儕乕僯儞僌偵傛傞傾億僩乕僔僗偲RNA姳徛傪慻傒崌傢偣偨暋崌娻帯椕丏嬥尨堦榊婰擮堛妛堛椕怳嫽嵿抍 戞25夞婎慴堛妛堛椕尋媶彆惉嬥丏
12. 幁搰棟嵐丏p53僼傽儈儕乕僉儊儔堚揱巕偵傛傞怴婯偑傫帯椕朄偺奐敪丏岞塿嵿抍朄恖 廐嶳婰擮惗柦壢妛怳嫽嵿抍 暯惉22擭搙尋媶彆惉乮彠椼彆惉乯
13. 幁搰棟嵐丏擕娻偵偍偗傞怴婯娻梷惂堚揱巕CHFR (Checkpoint with forkhead and ring finger domains)偺婡擻夝柧偲恌抐丒帯椕傊偺墳梡丏岞塿嵿抍朄恖恄郪堛妛尋媶怳嫽嵿抍 暯惉22擭搙尋媶彆惉
14. 幁搰棟嵐丏擕娻偵偍偗傞怴婯娻梷惂堚揱巕CHFR偲PARP-1憡屳嶌梡偺夝愅偲恌抐丒帯椕傊偺墳梡岞塿怣戸彫栰偑傫尋媶彆惉婎嬥 暯惉23擭尋媶彆惉丏
15. 幁搰棟嵐丏The functional relationship between CHFR and PARP-1 controls the antephase checkpoint and tumor development丏嵿抍朄恖嬥尨堦榊婰擮堛妛堛椕怳嫽嵿抍 暯惉22擭搙壓婜彆惉婎嬥乮尋媶岎棳彆惉嬥乯
16. 墶揷堢巕丏娾郪傦偄娻尋媶彆惉婎嬥 暯惉22擭搙彠椼嬥丏